Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer

被引：0
|
作者：
Bae, S. Y. [1 ]
Nam, S. J. [1 ]
Lee, S. K. [1 ]
Kim, S. W. [1 ]
Lee, J. E. [1 ]
Yu, J. H. [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-09-36
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-36
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [22] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [23] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Zheng, Hongjuan
    Ge, Chenyang
    Lin, Haiping
    Wu, Lunpo
    Wang, Qinghua
    Zhou, Shishi
    Tang, Wanfen
    Zhang, Xia
    Jin, Xiayun
    Xu, Xifeng
    Hong, Zhongwu
    Fu, Jianfei
    Du, Jinlin
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1145 - 1153
  • [24] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Hongjuan Zheng
    Chenyang Ge
    Haiping Lin
    Lunpo Wu
    Qinghua Wang
    Shishi Zhou
    Wanfen Tang
    Xia Zhang
    Xiayun Jin
    Xifeng Xu
    Zhongwu Hong
    Jianfei Fu
    Jinlin Du
    International Journal of Clinical Oncology, 2022, 27 : 1145 - 1153
  • [25] Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
    Rosalba Torrisi
    Valentina Vaira
    Laura Giordano
    Annarita Destro
    Vera Basilico
    Saveria Mazzara
    Piermario Salvini
    Gabriella Gaudioso
    Bethania Fernandes
    Noemi Rudini
    Giovanna Masci
    Armando Santoro
    Scientific Reports, 12
  • [26] Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
    Torrisi, Rosalba
    Vaira, Valentina
    Giordano, Laura
    Destro, Annarita
    Basilico, Vera
    Mazzara, Saveria
    Salvini, Piermario
    Gaudioso, Gabriella
    Fernandes, Bethania
    Rudini, Noemi
    Masci, Giovanna
    Santoro, Armando
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [27] Comparison of EndoPredict and MammaPrint in hormone receptor positive, HER2 negative breast cancer
    Boesl, A.
    Spitzmueller, A.
    Haid, A.
    Jasarevic, Z.
    Baruschke, K.
    Jaeger, S.
    Offner, F.
    BREAST, 2015, 24 : S46 - S47
  • [28] HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer
    Chaudhary, Lubna N.
    Jorns, Julie
    Gonyo, MaryBeth
    Kong, Amanda
    Peck, Amy R.
    Sun, Yunguang
    Bergom, Carmen
    Banarjee, Anjishnu
    Chitambar, Christopher
    Rui, Hallgeir
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Baseline serum extracellular domain HER2 expression in hormone receptor-positive metastatic breast cancer: correlation with known tissue HER2 status
    Johnston, S.
    O'Rouke, L.
    Wang, W.
    Pegram, M.
    Press, M. F.
    Maltzman, J.
    CANCER RESEARCH, 2009, 69 (02) : 246S - 247S
  • [30] Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Pegram, Mark
    Jackisch, Christian
    Johnston, Stephen R. D.
    NPJ BREAST CANCER, 2023, 9 (01)
12345